Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 4.80
- Piotroski Score 3.00
- Grade Buy
- Symbol (OCUL)
- Company Ocular Therapeutix, Inc.
- Price $10.11
- Changes Percentage (-4.67%)
- Change -$0.5
- Day Low $9.88
- Day High $10.74
- Year High $11.78
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology. The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD). Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/14/2024
- Fiscal Year End N/A
- Average Stock Price Target $16.00
- High Stock Price Target $24.00
- Low Stock Price Target $14.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.12
- Trailing P/E Ratio -4.41
- Forward P/E Ratio -4.41
- P/E Growth -4.41
- Net Income $-80,736,000
Income Statement
Quarterly
Annual
Latest News of OCUL
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Opinion | I Don't Want to Live in a Monoculture, and Neither Do You
The author reflects on the failures of diversity programs at the University of Michigan and the dangers of ideological monocultures in both left and right-wing institutions. Intellectual diversity and...
By The New York Times | 3 weeks ago -
Your new outdoor sidekick -- night vision binoculars with HD recording
Elevate your outdoor adventures with Mini Digital Night Vision Binoculars for $89.97 until September 3. Capture high-quality photos and videos in complete darkness with 1080p HD display, 4x digital zo...
By New York Post | 2 months ago -
The one-year returns have been notable for Ocular Therapeutix (NASDAQ:OCUL) shareholders despite underlying losses increasing
Passive investing in index funds can match the market, but picking high-performing stocks like Ocular Therapeutix (OCUL) can boost returns. Despite a recent rise, it's important to assess factors like...
By Yahoo! Finance | 4 months ago
